Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
13th Nov 2006, 16:15 GMT
Favrille, a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced that the Data Monitoring Committee completed its prospectively planned interim analysis of a secondary endpoint in the 1st 233 patients enrolled in the Company's ongoing pivotal, placebo-controlled Phase 3 clinical trial of FavId following Rituxan induction therapy in patients with follicular B- cell non-Hodgkin's lymphoma.
Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma related news:
- Favrille Announces Interim Analysis Of Secondary Endpoint From Pivotal Phase 3 Clinical Trial Of FavId Following Rituxan — Health News from Medical News Today
- Favrille drug fails secondary goal — Pharmaceutical Business Review Latest News
- Favrille Drug Misses Secondary Target — Pharmaceuticals News from StratCenter.com
- Human Genome Sciences Announces Positive 76-Week Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus — PR Newswire: All Releases
- Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting — Partnerships/ Joint Ventures News from StratCenter.com
- Kensey Nash Announces Commencement of Carotid Pivotal Trial for TriActiv ProGuard System — PR Newswire: All Releases
- Favrille 3Q Loss Widens on Costs — StratWire - Business of Healthcare NewsFeed
- Targeted Genetics Corporation: Interim Data on Use of tgAAC94 in the Treatment of Inflammatory Arthritis Presented at the American College of Rheumatology Meeting — Market Wire - Pharmaceuticals and Biotech
- Drug Rituxan linked to bowel problems, Health Canada advises — CBC | Health News
- Scientists Design A PSA-activated Protoxin That Kills Prostate Cancer: Phase I Clinical Trial Is Under Way — Health News from Medical News Today
Latest news from Bio-Technology News from StratCenter.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress
- Tanox shares soar in wake of Genentech buyout